These two autoinhibitory interactions are disrupted by activating mutations (e.g. F1174L, R1275Q) in ALK in neuroblastoma that drive kinase activity (Bossi et al, 2010; Lee et al, 2010; Bresler et al, 2014). The gene discussed is ALK; the disease is neuroblastoma.